RIVA-DM: Effectiveness and Safety of Rivaroxaban vs. Warfarin in Nonvalvular Atrial Fibrillation and Diabetes Mellitus: Analysis of Electronic Health Record Data

Study identification

• EU PAS number:
  EUPAS36634
• Study ID:
  47671
• Official title and acronym:
  RIVA-DM: Effectiveness and Safety of Rivaroxaban vs. Warfarin in Nonvalvular Atrial Fibrillation and Diabetes Mellitus: Analysis of Electronic Health Record Data
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Finalised

Research institutions and networks

Institutions

Bayer AG

Study timelines

Date when funding contract was signed

Planned:02/07/2020

Actual:02/07/2020

Study start date

Planned:21/08/2020

Actual:21/08/2020

Data analysis start date

Planned:31/07/2021

Actual:31/07/2021

Date of final study report

Planned:31/10/2021

Actual:05/11/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bayer AG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable